Molecular Cancer · 2025 · 24 citations · 297 references
MedicineImmunologyOncologyInflammationInnate ImmunityTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyInflammasome ActivationInflammatory SignalingTumor Immune MicroenvironmentTumor Microenvironment ModulationAntitumor Immune ActivationDamage-associated Molecular PatternsGasdermin D-mediated PyroptosisInflammasome ResponsesInnate Antitumor ImmunityNlr Family Pyrin Domain-containing 3 InflammasomePyroptosis MechanismsPyroptotic Cell Death
Pyroptosis, a caspase-dependent form of inflammatory programmed cell death, is driven by inflammasome activation and gasdermin-mediated membrane pore formation. Its immunogenic nature has attracted increasing attention in oncology, particularly for overcoming therapeutic challenges such as chemoresistance, radiotherapy failure, and immune checkpoint blockade non-responsiveness. By promoting the release of pro-inflammatory cytokines and damage-associated molecular patterns (DAMPs), pyroptosis can enhance antitumor immunity and reshape the tumor microenvironment (TME). However, sustained or dysregulated pyroptosis can lead to chronic inflammation, radiotherapy-induced tissue injury, and tumorigenesis, making it a double-edged sword. Emerging evidence shows that pyroptosis exhibits cancer-type-specific roles, depending on the molecular context and the extent of activation. Therefore, understanding the molecular regulators, tumor-specific signaling, and temporal dynamics of pyroptosis is essential for its therapeutic modulation. This review comprehensively outlines the dual roles of pyroptosis in cancer progression and treatment, discusses its molecular mechanisms, and highlights recent strategies to harness or suppress pyroptosis for therapeutic gain. Targeting pyroptosis offers a promising, yet complex, avenue for immune-enhancing cancer therapies.
297
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Yupeng Wang, Wenqing Gao, Xuyan Shi et al. · Nature · 2017 · 3.2K citations
Gasdermin E suppresses tumour growth by activating anti-tumour immunity
Zhibin Zhang, Ying Zhang, Shiyu Xia et al. · Nature · 2020 · 1.7K citations · Full text
Medicine, Immunology, Oncology +16
Deependra Singh, Jérôme Vignat, Valentina Lorenzoni et al. · The Lancet Global Health · 2022 · 1.5K citations · Full text
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
Zhiwei Zhou, Huabin He, Kun Wang et al. · Science · 2020 · 1.3K citations
Life Sciences, Immunology, Oncology +17